Northwest Biotherapeutics | NWBO - Current Liabilities


Northwest Biotherapeutics reported $87.9M in Current Liabilities for its fiscal quarter ending in September of 2025.





Current Liabilities Change Date
Agenus USD 287.13M 52.57M Sep/2025
AstraZeneca USD 30.62B 3.44B Dec/2025
Bristol-Myers Squibb USD 28.14B 608M Sep/2025
Celldex Therapeutics USD 46.46M 13.5M Sep/2025
Eisai JPY 387.67B 9.42B Dec/2025
Infinity Pharmaceuticals USD 12.06M 775K Jun/2023
Merck USD 28.63B 2.59B Sep/2025
Northwest Biotherapeutics USD 87.9M 3.98M Sep/2025
Pfizer USD 36.6B 1.13B Sep/2025
Plus Therapeutics USD 10.73M 189K Dec/2023
Roche Holding CHF 28B 421M Dec/2025